News|Articles|November 23, 2023

What Are You Thankful for This Year?

Tell us what you're thankful for!

We at Psychiatric Times are so thankful for YOU, our readers and contributors! Today, and all days, thank you for everything you do as mental health clinicians!

What are you most thankful for?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Endangered Education: Psychiatric Professional Degrees Under Attack

BySara Sethness, DNP, RN, PMHNP-BC,Lee Moore, DNP, MEd, CRNP-PMH, PMHNP-BC, CNE

June 2nd 2026

Psychiatry Does Not Need a Softer DSM. It Needs a Smarter One.

ByGarrett Rossi, MD

April 30th 2026

Psychedelics Deserve Real Science

ByGarrett Rossi, MD

April 22nd 2026

High-Potency Cannabis: America's New Pastime and Psychiatry's Next Challenge

ByGarrett Rossi, MD

April 16th 2026

When Pills Are Not the Answer: Rethinking the Psychiatrist’s Script

ByGarrett Rossi, MD

April 9th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

What Are You Thankful for This Year?

Related Content

Endangered Education: Psychiatric Professional Degrees Under Attack

Psychiatry Does Not Need a Softer DSM. It Needs a Smarter One.

Psychedelics Deserve Real Science

High-Potency Cannabis: America's New Pastime and Psychiatry's Next Challenge

When Pills Are Not the Answer: Rethinking the Psychiatrist’s Script

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

Suicide Risk Assessment in Patients Denying Suicidal Intent

Podcast: Early Intervention & Psychopharmacology in Bipolar Disorder With Robert M. Post, MD

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research